GlassScriptPhysician profile
Russell D Ingram
NPI 1043475353
$2,269.40
in general payments reported to CMS, 2019-2025
30 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $340 · 2021: $593 · 2022: $233 · 2023: $192 · 2024: $358 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $350.73 | 2019-2025 | |
| Abbvie INC. | $290.62 | 2021-2024 | |
| Glaxosmithkline, LLC. | $241.16 | 2020-2024 | Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $227.26 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $149.04 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $148.00 | 2020-2025 | Airsupra |
| Astellas Pharma US INC | $133.92 | 2019-2024 | Veozah |
| Abbott Laboratories | $127.54 | 2021-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $65.55 | 2023-2024 | Intellis Adaptivestim |
| Supernus Pharmaceuticals, INC. | $64.60 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $56.91 | 2020-2021 | |
| Amgen INC. | $55.89 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $49.59 | 2019-2021 | |
| Lilly USA, LLC | $39.86 | 2021-2023 | Zepbound, Jardiance |
| Horizon Therapeutics Plc | $29.08 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $26.74 | 2025 | Nexplanon |
| Si-Bone, INC. | $23.39 | 2021 | |
| Vyera Pharmaceuticals, LLC | $21.09 | 2019 | |
| Kci USA, INC. | $20.59 | 2023 | Promogran Prisma, Activ.A.C., 3m Cavilon |
| Edwards Lifesciences Corporation | $19.95 | 2022 | |
| Kaleo, INC. | $16.63 | 2021 | |
| Eisai INC. | $14.44 | 2021 | |
| Genentech USA, INC. | $14.25 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.06 | 2021 | |
| Esperion Therapeutics, INC. | $13.85 | 2021 | |
| Bardy Diagnostics, INC. | $12.93 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.70 | 2020 | |
| Amarin Pharma, INC. | $11.18 | 2020 | |
| Allergan, INC. | $10.99 | 2020 | |
| Neuronetics, INC. | $6.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.